Granza Bio develops a precision shell platform that utilizes autonomous "attack particles" from cytotoxic immune cells to deliver therapeutic cargo directly to cancer cells and hard-to-reach tissues. This technology minimizes toxicity and adverse side effects, enhancing the effectiveness of treatments for cancer and autoimmune diseases.
Funding
$7.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for delivering therapeutic payloads to cancer cells and other diseased tissues often lack precision, leading to off-target effects and systemic toxicity. Traditional delivery vehicles can trigger unwanted immune responses and struggle to reach difficult-to-access organs.
Solution
Granza Bio is developing a precision shell platform that leverages naturally occurring "attack particles" derived from cytotoxic immune cells to selectively deliver therapeutic cargo. These autonomous particles are engineered to target cancer cells and other diseased tissues directly, minimizing exposure to healthy cells and reducing adverse side effects. The platform is designed to accommodate a variety of cargo types, including RNAs, proteins, and genetic modifiers, offering versatility in therapeutic applications. By utilizing the immune system's own mechanisms, Granza Bio aims to overcome immunological barriers and improve the efficacy of treatments for cancer, autoimmune diseases, and infections. The technology facilitates delivery to a range of tissue sites and hard-to-reach organs.
Target Audience
Granza Bio's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer, autoimmune diseases, and infectious diseases.
Features
- Utilizes "attack particles," autonomous killing entities released from cytotoxic immune cells, for targeted delivery.
- Platform can deliver a variety of cargo types, including attack particles, RNAs, proteins, and genetic modifiers.
- Designed to overcome immunological activation triggered by the delivery vehicle.
- Capable of delivering to a range of tissue sites and hard-to-reach organs.